Pliant Therapeutics (FRA:9PT) Valuation Rank

View and export this data going back to 2020. Start your Free Trial

What is Pliant Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Pliant Therapeutics Valuation Rank Related Terms

Thank you for viewing the detailed overview of Pliant Therapeutics's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Pliant Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pliant Therapeutics Inc (FRA:9PT) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

PLRX:USA

Address

260 Littlefield Avenue, South San Francisco, CA, USA, 94080

Website

https://www.pliantrx.com

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.